Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

N-acetyltransferase 2 phenotype may be associated with susceptibility to age-related cataract.

Authors: Tamer, L  Yilmaz, A  Yildirim, H  Ayaz, L  Ates, NA  Karakas, S  Oz, O  Yildirim, O  Atik, U 
Citation: Tamer L, etal., Curr Eye Res. 2005 Oct;30(10):835-9.
Pubmed: (View Article at PubMed) PMID:16251120
DOI: Full-text: DOI:10.1080/02713680591003799

Free radicals and oxidative damage play roles in aging and age-related ocular diseases such as cataracts, so defensive mechanisms become important factors for protection. Because N-acetylation is involved in a wide variety of detoxification processes, this study was conducted to examine the relationship between the acetylator phenotypes and genotypes in a group of patients with age-related cataract. Sixty-one cases of age-related cataract and 104 controls were included in this study. Blood was collected in EDTA-containing tubes, and genomic DNA was extracted from the white blood cells by high pure PCR template preparation kit. Genotyping of NAT2 polymorphisms were detected by using a LightCycler-NAT2 mutation detection kit in real-time PCR. There was a significant difference in the distribution of the NAT2*6A acetylator phenotype between cases and the controls. The odds ratio of cataract for the NAT2*6A slow phenotype was 3.8 (95% CI = 1.08 to 13.11, p = 0.032) compared with the fast type. Our results suggest that slow acetylators are at higher risk of developing age-related cataracts than fast acetylators. As NAT2 is an important xenobiotic-metabolizing enzyme and theoretically xenobiotics such as ultraviolet B radiation, smoking, and alcohol use may induce cataract formation, NAT2 gene polymorphisms may be associated with genetic susceptibility of cataract.


Disease Annotations
Objects Annotated
Objects referenced in this article

Additional Information

RGD Object Information
RGD ID: 8552653
Created: 2014-04-23
Species: All species
Last Modified: 2014-04-23
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.